Brenntag SE Stock Timeline

2026-08-13 — Market reference price: 61.14

Latest authoritative market price for Brenntag (BNR.XETRA) as of this date. Used as the anchor for valuation and technical context in this timeline. [1]

2026 H1 (Q2 update, guidance raise) — June–August 2026

Q2 2026 results showed recovery with sales of €4.3bn (up 11% year-over-year), operating gross profit of €1,146m (up 19%), and operating EBITDA of €463m (up 41%). The company raised full-year 2026 operating EBITDA guidance to €1,250–1,400m and announced a cost-out target of €200–250m by 2027. The Woojin Trading acquisition is expected to close in Q4 2026. Free cash flow remained weak due to working capital build. [3][7]

After soft H1 demand, investors responded positively to margin recovery and the guidance raise. The narrative shifted from cautious cyclical exposure toward confidence in pricing discipline and cost measures, though concerns about working capital and cash conversion persisted. Price rebounded from earlier weakness as results and guidance beat expectations. [3]

2026 Q1 — May 2026

Q1 2026 results showed sales of €3.7bn (down 5.1% year-over-year), operating gross profit of €950m (down 1.3%), and operating EBITDA of €306m (down 8.3%). Management highlighted weak demand but noted improved pricing momentum. Higher working capital reduced free cash flow to €91m compared to €163m in the prior period. [1][9]

The market perceived the quarter as resilient amid macro softness. Investors remained cautious on the second half but were encouraged by margin resilience and cost actions. The stock was treated as cyclical with evidence that management could defend margins. Price formed a base for the subsequent Q2 rebound. [1]

Full-year 2025 results and impairment impact — March 2026 reporting season

FY2025 revenue was approximately €15.2bn (down 7% year-over-year), with operating EBITDA of approximately €1.29bn (down 12% year-over-year). Consolidated net profit attributable to shareholders nearly halved to €265m, primarily due to impairment charges. The Annual Report 2025 showed Operating Gross Profit of €3.8bn and Operating EBITA of €929m. A dividend of €1.90 per share was proposed. [15][14]

Investor sentiment shifted from the exceptional 2021–2022 growth period toward recognition of normalization and cyclical downturn, compounded by one-off impairments. The stock was seen as recovering from excesses but requiring structural margin actions to restore growth. The maintained dividend supported income investors. Price reflected re-valuation on lower earnings and impairment news. [14][15]

2024 — Strategic execution and integration

The company emphasized Strategy to Win execution through governance redesign, division focus (Brenntag Essentials and Brenntag Specialties), and ongoing cost-out measures. Management was reorganized to drive margin improvement, with continued M&A integration from prior years and selective bolt-on acquisitions. [8]

Investors began viewing Brenntag as focused on operational improvement and higher-margin mix, reframing the story from pure volume growth toward margin quality and integration value capture. Price showed occasional rallies on positive cost and outlook news with gradual uptrend in sentiment, though gains were muted until concrete earnings evidence appeared. [8]

2023 — Management reshuffle and governance changes — August 2023

The Management Board was redesigned with creation of a two-division governance structure and appointment of Ewout van Jarwaarde as CEO Brenntag Essentials. Steven Terwindt left the Board. Strategic realignment occurred under "Strategy to Win." [8]

Investors viewed this positively as sharper accountability and focus on Essentials versus Specialties, though short-term execution risk existed. The medium-term credibility boost for structural improvement was noted. Price stabilized following the announcement as markets awaited execution. [8]

2022 — Peak performance year and capital return program

FY2022 delivered record results: sales of €19.43bn (up 27.7% year-over-year), operating gross profit of €4.319bn (up 20.3%), and operating EBITDA of €1.809bn (up 26.7%). The company announced an attractive share buyback program and proposed dividend increase. Strong 2023 outlook was provided. [13][2]

The market portrayed Brenntag as a high-quality distributor benefiting from supply disruptions and pricing tailwinds. The bullish growth narrative peaked, with share buybacks and higher dividend reinforcing shareholder-friendly perception. Strong uptrend and multiple expansions culminated in 2022 highs with euphoric sentiment as the company delivered record numbers. [13]

2021 — Exceptional market conditions and record FY2021 results

Brenntag reported record FY2021 results driven by supply chain tightness and pricing power. Operating gross profit increased 19.6% to €3.379bn, and operating EBITDA reached €1.345bn (up 29.5%). Management provided a strong 2022 outlook. [4]

Investor perception shifted from steady distributor to an outsized beneficiary of post-pandemic supply dynamics, viewed as a growth and margin capture story. This set the stage for 2022 record performance and subsequent re-rating. The beginning of the strong multi-year uptrend that would culminate in 2022 peaks marked the momentum phase. [4]